ACTIVE INGREDIENT
Active Ingredient: Sodium hyaluronate 95.0%
Active Ingredient: Sodium hyaluronate 95.0%
Inactive Ingredient: Lactose
Purpose: Skin Protectant
Warnings: 1. Do not use if irritation occurs. 2. Avoid using on sensitive skin. 3. Keep out of reach of children 4. For external use only. 5. Store in a cool place
Keep out of reach of babies and children
Indications & usage:1. Take a patch out of the pouch with dry hand after face washing. 2. Try not to touch the middle side (needle) and take off the protective film carefully. 3. Place and attach the middle side of the patch on a desired area vertically. 4. Press the middle part of the patch attached with fingers several times. 5. Go to bed with patch attached and take it off the next morning.
Dosage & Administration: 2-3 times a week.
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 70018-010-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-2176-f424-e053-dadaa90a57ce | 9aa06328-b8c2-47b7-9281-15e4da8f2745 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70018-010-01 | Hyaluronic Acid Micro | 4 in 1 CARTON | PATCH | 4 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| HYALURONATE SODIUM | ACTIVE INGREDIENT | YSE9PPT4TH | 1 | |
| HYALURONIC ACID | ACTIVE MOIETY | S270N0TRQY | 1 | |
| Lactose | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 70018-010 | 70018-010-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYALURONATE SODIUM | YSE9PPT4TH | ACTIB |
| Lactose | J2B2A4N98G | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| Lactose | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| Lactose | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| Lactose | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| Lactose | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ec76fa73-3967-4ae1-8e95-0f5e00d0c8e4 | 9aa06328-b8c2-47b7-9281-15e4da8f2745 | 2015-08-06 | Warnings | ec76fa73-3967-4ae1-8e95-0f5e00d0c8e4 9aa06328-b8c2-47b7-9281-15e4da8f2745 |
Adverse event summaries are temporarily unavailable. Other product information remains available.